Novel synthetic bis-indolic derivatives with antistaphylococcal activity, including against MRSA and VISA strains

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 6, 2014, Pages 1727-1737

  Caspar, Yvan ^a,b   Jeanty, Matthieu ^b,d   Blu, Jérôme ^b   Burchak, Olga ^b,e   Le Pihive, Emmanuelle ^b   Maigre, Laure ^b   Schneider, Dominique ^b   Jolivalt, Claude ^c,f   Paris, Jean Marc ^c   Hequet, Arnaud ^c,g   Minassian, Frédéric ^b   Denis, Jean Noël ^b   Maurin, Max ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d Novalix   (France)

^e CEA GRENOBLE   (France)

^f UNIVERSITÉ PIERRE ET MARIE CURIE   (France)

^g UNIVERSITÉ DE POITIERS   (France)

Author keywords

Antibiotics; Bis indoles; Drug development; Drug susceptibility testing; Efflux pumps; Staphylococci

Indexed keywords

BACTERICIDE; CIPROFLOXACIN; GENTAMICIN; INDOLE ALKALOID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ALKALOID; ANTIINFECTIVE AGENT; HAMACANTHINE A; IMIDAZOLE DERIVATIVE; IMIDAZOLINE DERIVATIVE; INDOLE DERIVATIVE; PYRAZINE DERIVATIVE; SPONGOTINE A; TOPSENTIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORA GENE; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; STAPHYLOCOCCUS; STAPHYLOCOCCUS ARLETTAE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS CAPITIS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS HOMINIS; STAPHYLOCOCCUS LUGDUNENSIS; STAPHYLOCOCCUS MASSILIENSIS; STAPHYLOCOCCUS PETTENKOFERI; STAPHYLOCOCCUS SAPROPHYTICUS; STAPHYLOCOCCUS SCIURI; STAPHYLOCOCCUS SIMULANS; STAPHYLOCOCCUS WARNERI; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; SYNTHESIS; TIME;

ALKALOIDS; ANTI-BACTERIAL AGENTS; HUMANS; IMIDAZOLES; IMIDAZOLINES; INDOLE ALKALOIDS; INDOLES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MOLECULAR STRUCTURE; PYRAZINES; STAPHYLOCOCCUS; TIME FACTORS;

EID: 84930520829     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv015     Document Type: Article

References (53)

1. Hamad B. The antibiotics market. Nat Rev Drug Discov 2010; 9: 675-6.
2. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
3. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003; 6: 427-30.
4. Munoz-Bellido JL, Manzanares MAA, Andres JAM et al. Efflux pumpmediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob Agents Chemother 1999; 43: 354-6.
5. Tanaka M, Wang T, Onodera Y et al. Mechanism of quinolone resistance in Staphylococcus aureus. J Infect Chemother 2000; 6: 131-9.
6. Kaatz GW, Seo SM, Ruble CA. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993; 37: 1086-94.
7. Van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54: 755-71.
8. Van Hal SJ, Fowler VG. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis 2013; 56: 1779-88.
9. Lewis K. Antibiotics: recover the lost art of drug discovery. Nature 2012; 485: 439-40.
10. Kumar K, Chopra S. New drugs for methicillin-resistant Staphylococcus aureus: an update. J Antimicrob Chemother 2013; 68: 1465-70.
11. Wenzel RP. The antibiotic pipeline: challenges, costs, and values. N Engl J Med 2004; 351: 523-6.
12. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci 2011; 1241: 48-70.
13. Vilhena C, Bettencourt A. Daptomycin: a review of properties, clinical use, drug delivery and resistance. Mini Rev Med Chem 2012; 12: 202-9.
14. Robbel L, Marahiel MA. Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery. J Biol Chem 2010; 285: 27501-8.
15. Bayer AS, Schneider T, Sahl H-G. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 2013; 1277: 139-58.
16. Long KS, Vester B. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother 2012; 56: 603-12.
17. Gul W, Hamann MT. Indole alkaloid marine natural products: an established source of cancer drug leads with considerable promise for the control of parasitic, neurological and other diseases. Life Sci 2005; 78: 442-53.
18. Guinchard X. Chimie des nitrones: applications en synthèse organique et à la synthèse de composés bio-actifs. PhD Thesis. Université Joseph Fourier, Grenoble, France, 2006.
19. Oh K-B, Mar W, Kim S et al. Antimicrobial activity and cytotoxicity of bis(indole) alkaloids from the sponge Spongosorites sp. Biol Pharm Bull 2006; 29: 570-3.
20. Guinchard X, Vallée Y, Denis J-N. Total syntheses of brominated marine sponge alkaloids. Org Lett 2007; 9: 3761-4.
21. Guinchard X, Vallée Y, Denis J-N. Total synthesis of marine sponge bis(indole) alkaloids of the topsentin class. J Org Chem 2007; 72: 3972-5.
22. Burchak ON, Pihive EL, Maigre L et al. Synthesis and evaluation of 1-(1H-indol-3-yl)ethanamine derivatives as new antibacterial agents. Bioorg Med Chem 2011; 19: 3204-15.
23. Hequet A, Burchak ON, Jeanty M et al. 1-(1H-Indol-3-yl)ethanamine derivatives as potent Staphylococcus aureus NorA efflux pump inhibitors. ChemMedChem 2014; 9: 1534-45.
24. Denis J-N, Guinchard X, Moreau N et al. Synthesis of new indole derivatives, their preparation processes, and their antibacterial uses. September 2008. PCT Int Appl, WO 2008110690 A2 20080918.
25. Denis J-N, Jolivalt C, Maurin M et al. Preparation of novel bis-indolic derivatives antibacterial drugs and a process for preparing them. January 2013. PCT Int Appl, WO 2013014102 A1 20130131.
26. Denis J-N, Jolivalt C, Maurin M et al. Preparation of bis-indole derivatives useful as antibacterials. January 2013. PCT Int Appl, WO 2013014104 A1 20130131.
27. Bergeron M, Dauwalder O, Gouy M et al. Species identification of staphylococci by amplification and sequencing of the tuf gene compared to the gap gene and by matrix-assisted laser desorption ionization timeof- flightmass spectrometry. Eur J ClinMicrobiol Infect Dis 2011; 30: 343-54.
28. Sabatini S, Gosetto F, Manfroni G et al. Evolution from a natural flavones nucleus to obtain 2-(4-propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump. J Med Chem 2011; 54: 5722-36.
29. National Committee for Clinical Laboratory Standards. Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. NCCLS, Wayne, PA, USA, 1999.
30. Oravcova J, Böhs B, Lindner W. Drug-protein binding studies new trends in analytical and experimental methodology. J Chromatogr B Biomed Sci App 1996; 677: 1-28.
31. oct) from gradient RP-HPLC retention and a hydrogen bond acidity term (Sigma alpha2H). Curr Med Chem 2001; 8: 1137-46.
32. Gould IM, Cauda R, Esposito S et al. Management of serious meticillinresistant Staphylococcus aureus infections: what are the limits? Int J Antimicrob Agents 2011; 37: 202-9.
33. Bao B, Sun Q, Yao X et al. Bisindole alkaloids of the topsentin and hamacanthin classes from a marine sponge Spongosorites sp. J Nat Prod 2007; 70: 2-8.
34. Casapullo A, Bifulco G, Bruno I et al. New bisindole alkaloids of the topsentin and hamacanthin classes from the Mediterranean marine sponge Rhaphisia lacazei. J Nat Prod 2000; 63: 447-51.
35. Gunasekera SP, McCarthy PJ, Kelly-Borges M. Hamacanthins A and B, new antifungal bis indole alkaloids from the deep-water marine sponge, Hamacantha sp. J Nat Prod 1994; 57: 1437-41.
36. Bao B, Sun Q, Yao X et al. Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp. J Nat Prod 2005; 68: 711-5.
37. Wright AE, Pomponi SA, Cross SS et al. A new bis-(indole) alkaloid from a deep-water marine sponge of the genus Spongosorites. J Org Chem 1992; 57: 4772-5.
38. Zoraghi R, Worrall L, See RH et al. Methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase as a target for bis-indole alkaloids with antibacterial activities. J Biol Chem 2011; 286: 44716-25.
39. Panchal RG, Ulrich RL, Lane D et al. Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibioticresistant strains. Antimicrob Agents Chemother 2009; 53: 4283-91.
40. Butler MM, Williams JD, Peet NP et al. Comparative in vitro activity profiles of novel bis-indole antibacterials against Gram-positive and Gram-negative clinical isolates. Antimicrob Agents Chemother 2010; 54: 3974-7.
41. Panchal RG, Lane D, Boshoff HI et al. Bis-imidazolinylindoles are active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Mycobacterium tuberculosis. J Antibiot (Tokyo) 2013; 66: 47-9.
42. Jacobs MR, Bajaksouzian S, Good CE et al. Novel bis-indole agents active against multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2011; 69: 114-6.
43. Kumar GS, Kumaresan S, Muthu Prabhu AA et al. An efficient one pot syntheses of aryl-3,3′-bis(indolyl)methanes and studies on their spectral characteristics, DPPH radical scavenging-, antimicrobial-, cytotoxicity-, and antituberculosis activity. Spectrochim Acta A Mol Biomol Spectrosc 2013; 101: 254-63.
44. Mielczarek M, Devakaram RV, Ma C et al. Synthesis and biological activity of novel bis-indole inhibitors of bacterial transcription initiation complex formation. Org Biomol Chem 2014; 12: 2882-94.
45. Oh K-B, Mar W, Kim S et al. Bis(indole) alkaloids as sortase A inhibitors from the sponge Spongosorites sp. Bioorg Med Chem Lett 2005; 15: 4927-31.
46. Zoraghi R, See RH, Axerio-Cilies P et al. Identification of pyruvate kinase in methicillin-resistant Staphylococcus aureus as a novel antimicrobial drug target. Antimicrob Agents Chemother 2011; 55: 2042-53.
47. Axerio-Cilies P, See RH, Zoraghi R et al. Cheminformatics-driven discovery of selective, nanomolar inhibitors for staphylococcal pyruvate kinase. ACS Chem Biol 2012; 7: 350-9.
48. Kumar NS, Dullaghan EM, Finlay BB et al. Discovery and optimization of a new class of pyruvate kinase inhibitors as potential therapeutics for the treatment of methicillin-resistant Staphylococcus aureus infections. Bioorg Med Chem 2014; 22: 1708-25.
49. Kumar NS, Amandoron EA, Cherkasov A et al. Optimization and structure-activity relationships of a series of potent inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase as novel antimicrobial agents. Bioorg Med Chem 2012; 20: 7069-82.
50. Caspar Y, Sutera V, Boisset S et al. Bis-indolic compounds as potential new therapeutic alternatives for tularaemia. Front Cell Infect Microbiol 2014; 4: 24.
51. Markham PN, Westhaus E, Klyachko K et al. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 2404-8.
52. Costa SS, Falcão C, Viveiros M et al. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol 2011; 11: 241.
53. Samosorn S, Tanwirat B, Muhamad N et al. Antibacterial activity of berberine-NorA pump inhibitor hybrids with a methylene ether linking group. Bioorg Med Chem 2009; 17: 3866-72.